WO2001003668A1 - Pulmonary delivery of liposome-encapsulated cannabinoids - Google Patents
Pulmonary delivery of liposome-encapsulated cannabinoids Download PDFInfo
- Publication number
- WO2001003668A1 WO2001003668A1 PCT/CA2000/000805 CA0000805W WO0103668A1 WO 2001003668 A1 WO2001003668 A1 WO 2001003668A1 CA 0000805 W CA0000805 W CA 0000805W WO 0103668 A1 WO0103668 A1 WO 0103668A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- cannabinoid
- thc
- tetrahydrocannabinol
- liposomes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59582/00A AU5958200A (en) | 1999-07-08 | 2000-07-07 | Pulmonary delivery of liposome-encapsulated cannabinoids |
JP2001508949A JP2003504321A (en) | 1999-07-08 | 2000-07-07 | Pulmonary delivery of liposome-encapsulated cannabinoids |
EP00945490A EP1109533A1 (en) | 1999-07-08 | 2000-07-07 | Pulmonary delivery of liposome-encapsulated cannabinoids |
CA002341035A CA2341035A1 (en) | 1999-07-08 | 2000-07-07 | Pulmonary delivery of liposomal-encapsulated cannabinoids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14279099P | 1999-07-08 | 1999-07-08 | |
US60/142,790 | 1999-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001003668A1 true WO2001003668A1 (en) | 2001-01-18 |
Family
ID=22501293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2000/000805 WO2001003668A1 (en) | 1999-07-08 | 2000-07-07 | Pulmonary delivery of liposome-encapsulated cannabinoids |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1109533A1 (en) |
JP (1) | JP2003504321A (en) |
AU (1) | AU5958200A (en) |
CA (1) | CA2341035A1 (en) |
WO (1) | WO2001003668A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066089A2 (en) * | 2000-03-09 | 2001-09-13 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabis |
WO2003006010A1 (en) * | 2001-07-10 | 2003-01-23 | Norton Healthcare Limited | Aerosol formulations of δ8 tetrahydrocannabinol |
GB2384707A (en) * | 2002-02-01 | 2003-08-06 | Gw Pharma Ltd | Compositions for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
WO2004037270A1 (en) * | 2002-10-25 | 2004-05-06 | Vasogen Ireland Limited | Cyclooxygenase regulation with pg liposomes |
WO2004037271A1 (en) * | 2002-10-25 | 2004-05-06 | Vasogen Ireland Limited | Cyclooxygenase regulation with ps liposomes |
JP2006504671A (en) * | 2002-08-14 | 2006-02-09 | ジーダブリュー ファーマ リミテッド | Cannabinoid liquid formulation for mucosal administration |
WO2007042811A1 (en) | 2005-10-12 | 2007-04-19 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease |
EP1696929A4 (en) * | 2003-11-05 | 2010-02-24 | Unimed Pharmaceuticals Inc | Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis |
US8034843B2 (en) | 2002-02-01 | 2011-10-11 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
US8119697B2 (en) | 2002-02-19 | 2012-02-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
EP2298283A3 (en) * | 2001-02-14 | 2012-12-26 | GW Pharma Limited | Pharmaceutical formulations comprising cannabinoids |
US20130089600A1 (en) * | 2011-07-11 | 2013-04-11 | Organic Medical Research | Cannabinoid formulations |
RU2493874C2 (en) * | 2007-03-30 | 2013-09-27 | Хирофуми ТАКЕУТИ | Transpulmonary liposome for controlling drug delivery |
US8628796B2 (en) | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
US8829043B2 (en) | 2008-02-08 | 2014-09-09 | Nektar Therapeutics | Oligome-cannabinoid conjugates |
US20160228362A1 (en) * | 2015-05-27 | 2016-08-11 | Ghasem Amoabediny | Targetted nano-liposome co-entrapping anti-cancer drugs |
US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
US10258601B1 (en) * | 2013-08-22 | 2019-04-16 | Stephen C. Perry | Vaporizable cannabinoid compositions |
WO2019140321A1 (en) | 2018-01-12 | 2019-07-18 | Nutrae, LLC | Encapsulated cannabinoid formulations for transdermal delivery |
US20190224193A1 (en) * | 2013-03-14 | 2019-07-25 | Christopher Brian Reid | Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
WO2020124268A1 (en) * | 2018-12-21 | 2020-06-25 | Botaneco Inc. | Cannabinoid formulations and methods of making same |
EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | Formulations |
EP3769752A1 (en) | 2019-07-26 | 2021-01-27 | Landsteiner Scientific S.A. de C.V. | Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications |
WO2021038574A1 (en) | 2019-09-01 | 2021-03-04 | Nextage Cannabis Innovation Ltd. | Cannabinoid containing targeting liposomes |
WO2021064730A1 (en) | 2019-10-03 | 2021-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Liposomal cannabinoids and uses thereof |
WO2021091905A1 (en) * | 2019-11-08 | 2021-05-14 | Vella Bioscience, Inc. | Liposomal formulations for delivery of cannabinoids and methods of making thereof |
US20220031616A1 (en) * | 2020-07-29 | 2022-02-03 | Matthew HALPERT | Aerosolized CBD Liposomes for the treatment of Asthma and other pulmonary inflammatory disorders |
US11260033B2 (en) | 2018-12-11 | 2022-03-01 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
US20220387352A1 (en) * | 2020-07-29 | 2022-12-08 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
US20230131989A1 (en) * | 2020-07-29 | 2023-04-27 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
WO2024025525A1 (en) * | 2022-07-27 | 2024-02-01 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5451408A (en) * | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
WO1997042938A1 (en) * | 1996-05-14 | 1997-11-20 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
US5716638A (en) * | 1994-06-22 | 1998-02-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composition for applying active substances to or through the skin |
WO2000027359A1 (en) * | 1998-11-12 | 2000-05-18 | Pilkiewicz Frank G | An inhalation system |
-
2000
- 2000-07-07 JP JP2001508949A patent/JP2003504321A/en active Pending
- 2000-07-07 AU AU59582/00A patent/AU5958200A/en not_active Abandoned
- 2000-07-07 WO PCT/CA2000/000805 patent/WO2001003668A1/en not_active Application Discontinuation
- 2000-07-07 CA CA002341035A patent/CA2341035A1/en not_active Abandoned
- 2000-07-07 EP EP00945490A patent/EP1109533A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5451408A (en) * | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
US5716638A (en) * | 1994-06-22 | 1998-02-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composition for applying active substances to or through the skin |
WO1997042938A1 (en) * | 1996-05-14 | 1997-11-20 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
WO2000027359A1 (en) * | 1998-11-12 | 2000-05-18 | Pilkiewicz Frank G | An inhalation system |
Non-Patent Citations (3)
Title |
---|
B.A. QUINTANA ET AL.: "Drug administration via a liposomal dosage form", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 25, no. 8, 1985, Stamford (US), pages 635, XP000971434 * |
CHEMICAL ABSTRACTS, vol. 107, no. 21, 23 November 1987, Columbus, Ohio, US; abstract no. 190621b, A.T. WATSON: "Effects of cannabinoids on selected myocardial biochemical pathways and evalution of a liposomal drug delivery system" page 43; column 1; XP002155316 * |
DISS. ABSTR. INT. B, vol. 48, no. 2, 1987, pages 399 * |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066089A3 (en) * | 2000-03-09 | 2002-02-21 | Gw Pharma Ltd | Pharmaceutical compositions comprising cannabis |
WO2001066089A2 (en) * | 2000-03-09 | 2001-09-13 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabis |
US8481091B2 (en) | 2000-03-09 | 2013-07-09 | Gw Pharma Limited | Pharmaceutical compositions |
US8512767B2 (en) | 2000-03-09 | 2013-08-20 | Gw Pharma Limited | Pharmaceutical compositions |
US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
CZ306277B6 (en) * | 2001-02-14 | 2016-11-09 | Gw Pharma Limited | Pump-action spray formulation |
EP2298283A3 (en) * | 2001-02-14 | 2012-12-26 | GW Pharma Limited | Pharmaceutical formulations comprising cannabinoids |
AU2002319422C1 (en) * | 2001-07-10 | 2008-05-01 | Norton Healthcare Limited | Aerosol formulations of delta8 tetrahydrocannabinol |
WO2003006010A1 (en) * | 2001-07-10 | 2003-01-23 | Norton Healthcare Limited | Aerosol formulations of δ8 tetrahydrocannabinol |
AU2002319422B8 (en) * | 2001-07-10 | 2003-01-29 | Norton Healthcare Limited | Aerosol formulations of delta8 tetrahydrocannabinol |
AU2002319422B2 (en) * | 2001-07-10 | 2007-10-18 | Norton Healthcare Limited | Aerosol formulations of delta8 tetrahydrocannabinol |
GB2384707A (en) * | 2002-02-01 | 2003-08-06 | Gw Pharma Ltd | Compositions for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
US8034843B2 (en) | 2002-02-01 | 2011-10-11 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
GB2384707B (en) * | 2002-02-01 | 2005-11-16 | Gw Pharma Ltd | Compositions for treatment of nausea,vomiting,emesis,motion sickness or like conditions |
US8119697B2 (en) | 2002-02-19 | 2012-02-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
JP2006504671A (en) * | 2002-08-14 | 2006-02-09 | ジーダブリュー ファーマ リミテッド | Cannabinoid liquid formulation for mucosal administration |
WO2004037271A1 (en) * | 2002-10-25 | 2004-05-06 | Vasogen Ireland Limited | Cyclooxygenase regulation with ps liposomes |
WO2004037270A1 (en) * | 2002-10-25 | 2004-05-06 | Vasogen Ireland Limited | Cyclooxygenase regulation with pg liposomes |
EP1696929A4 (en) * | 2003-11-05 | 2010-02-24 | Unimed Pharmaceuticals Inc | Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis |
US8628796B2 (en) | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
WO2007042811A1 (en) | 2005-10-12 | 2007-04-19 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease |
RU2493874C2 (en) * | 2007-03-30 | 2013-09-27 | Хирофуми ТАКЕУТИ | Transpulmonary liposome for controlling drug delivery |
US8658204B2 (en) | 2007-03-30 | 2014-02-25 | Otsuka Pharmaceutical Co., Ltd. | Transpulmonary liposome for controlling drug arrival |
US9750694B2 (en) | 2007-03-30 | 2017-09-05 | Hirofumi Takeuchi | Transpulmonary liposome for controlling drug arrival |
US8829043B2 (en) | 2008-02-08 | 2014-09-09 | Nektar Therapeutics | Oligome-cannabinoid conjugates |
US9155797B2 (en) | 2008-02-08 | 2015-10-13 | Nektar Therapeutics | Oligomer-cannabinoid conjugates |
US20160030387A1 (en) * | 2011-07-11 | 2016-02-04 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
US9095555B2 (en) | 2011-07-11 | 2015-08-04 | Full Spectrum Laboratories, Limited | Cannabinoid formulations |
US8808734B2 (en) * | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
US20130089600A1 (en) * | 2011-07-11 | 2013-04-11 | Organic Medical Research | Cannabinoid formulations |
US10052303B2 (en) | 2011-07-11 | 2018-08-21 | Teewinot Technologies Limited | Cannabinoid formulations |
US20190224193A1 (en) * | 2013-03-14 | 2019-07-25 | Christopher Brian Reid | Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases |
US10258601B1 (en) * | 2013-08-22 | 2019-04-16 | Stephen C. Perry | Vaporizable cannabinoid compositions |
US20160228362A1 (en) * | 2015-05-27 | 2016-08-11 | Ghasem Amoabediny | Targetted nano-liposome co-entrapping anti-cancer drugs |
US9855216B2 (en) * | 2015-05-27 | 2018-01-02 | Ghasem Amoabediny | Targeted nano-liposome co-entrapping anti-cancer drugs |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
US11304393B2 (en) | 2016-05-27 | 2022-04-19 | New West Genetics Inc. | Industrial hemp cannabis cultivars and seeds with stable cannabinoid profiles |
EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | Formulations |
WO2019140321A1 (en) | 2018-01-12 | 2019-07-18 | Nutrae, LLC | Encapsulated cannabinoid formulations for transdermal delivery |
WO2019140325A1 (en) | 2018-01-12 | 2019-07-18 | Nutrae, LLC | Encapsulated cannabinoid formulations for inhalation or injection |
WO2019140323A1 (en) | 2018-01-12 | 2019-07-18 | Nutrae, LLC | Encapsulated cannabinoid formulations for oral delivery |
US10709747B2 (en) | 2018-01-12 | 2020-07-14 | Nutrae, LLC | Encapsulated cannabinoid formulations for oral delivery |
US10709748B2 (en) | 2018-01-12 | 2020-07-14 | Nutrae, LLC | Encapsulated cannabinoid formulations for transdermal delivery |
US11260033B2 (en) | 2018-12-11 | 2022-03-01 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
WO2020124268A1 (en) * | 2018-12-21 | 2020-06-25 | Botaneco Inc. | Cannabinoid formulations and methods of making same |
EP3769752A1 (en) | 2019-07-26 | 2021-01-27 | Landsteiner Scientific S.A. de C.V. | Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications |
WO2021038574A1 (en) | 2019-09-01 | 2021-03-04 | Nextage Cannabis Innovation Ltd. | Cannabinoid containing targeting liposomes |
EP4021415A4 (en) * | 2019-09-01 | 2023-10-25 | Nextage Therapeutics Ltd. | Cannabinoid containing targeting liposomes |
WO2021064730A1 (en) | 2019-10-03 | 2021-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Liposomal cannabinoids and uses thereof |
WO2021091905A1 (en) * | 2019-11-08 | 2021-05-14 | Vella Bioscience, Inc. | Liposomal formulations for delivery of cannabinoids and methods of making thereof |
US20220031616A1 (en) * | 2020-07-29 | 2022-02-03 | Matthew HALPERT | Aerosolized CBD Liposomes for the treatment of Asthma and other pulmonary inflammatory disorders |
US20220387352A1 (en) * | 2020-07-29 | 2022-12-08 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
US20230131989A1 (en) * | 2020-07-29 | 2023-04-27 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
WO2024025525A1 (en) * | 2022-07-27 | 2024-02-01 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
Also Published As
Publication number | Publication date |
---|---|
AU5958200A (en) | 2001-01-30 |
EP1109533A1 (en) | 2001-06-27 |
CA2341035A1 (en) | 2001-01-18 |
JP2003504321A (en) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001003668A1 (en) | Pulmonary delivery of liposome-encapsulated cannabinoids | |
EP1888033B1 (en) | Method and composition for treating inflammatory disorders | |
US9980959B2 (en) | Method and composition for treating rhinitis | |
WO2019196129A1 (en) | Local anesthesia pain-relieving and sustained-release drug delivery system, as well as preparation method therefor and use thereof | |
US20090181080A1 (en) | Oral cannabinnoid liquid formulations and methods of treatment | |
BE1005952A4 (en) | Liposomes. | |
WO2021196659A1 (en) | Glycosyl polyether compound liposome, preparation method therefor and medicine thereof | |
IL148241A (en) | Composition for inhalation containing delta-9-tetrahydrocannabinol | |
WO1987005803A1 (en) | COMPOSITIONS OF LIPOSOMES AND beta2-RECEPTOR ACTIVE SUBSTANCES | |
WO2021064730A1 (en) | Liposomal cannabinoids and uses thereof | |
BG63327B1 (en) | Selegiline-containing liposome composition | |
EP0859598A1 (en) | Liposomes containing a corticosteroid | |
US20130005824A1 (en) | Treatment of ischemic tissue | |
Tabak et al. | Evaluation of a liposome system for the delivery of desferrioxamine to lungs in rats | |
JPH05501714A (en) | liposome composition | |
KR101198201B1 (en) | Method and composition for treating rhinitis | |
CN117813081A (en) | Cannabidiol esters for the treatment of Prader-Willi syndrome | |
CN1813905A (en) | Coated magnolia fargesii volatile oil nano liposome nasal drops |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2341035 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 59582/00 Country of ref document: AU Ref document number: 2000945490 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2001 508949 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2000945490 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000945490 Country of ref document: EP |